Published in Int J Mol Sci on January 23, 2014
A Pre-Cellular Therapy Observational Study in Early Huntington's Disease (PRE-CELL) | NCT01937923
Alzheimer's Disease: Mechanism and Approach to Cell Therapy. Int J Mol Sci (2015) 0.79
Role of Epigenetics in Stem Cell Proliferation and Differentiation: Implications for Treating Neurodegenerative Diseases. Int J Mol Sci (2016) 0.78
Analgesia for neuropathic pain by dorsal root ganglion transplantation of genetically engineered mesenchymal stem cells: initial results. Mol Pain (2015) 0.77
A possible new focus for stroke treatment - migrating stem cells. Expert Opin Biol Ther (2015) 0.76
Engineered Mesenchymal Cells Improve Passive Immune Protection Against Lethal Venezuelan Equine Encephalitis Virus Exposure. Stem Cells Transl Med (2016) 0.76
Generation of diverse neural cell types through direct conversion. World J Stem Cells (2016) 0.75
Mesenchymal Stem Cells from Human Extra Ocular Muscle Harbor Neuroectodermal Differentiation Potential. PLoS One (2016) 0.75
Manipulation of a quasi-natural cell block for high-efficiency transplantation of adherent somatic cells. Braz J Med Biol Res (2015) 0.75
Gene Therapy with Mesenchymal Stem Cells Expressing IFNßAmeliorates Neuroinflammation in Experimental Models of Multiple Sclerosis. Br J Pharmacol (2016) 0.75
Erythropoietin facilitates the recruitment of bone marrow mesenchymal stem cells to sites of spinal cord injury. Exp Ther Med (2017) 0.75
Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 37.55
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng (2001) 20.65
Pluripotency of mesenchymal stem cells derived from adult marrow. Nature (2002) 19.57
A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res (1961) 18.57
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59
Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet (2004) 11.77
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol (2013) 11.58
Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science (1997) 11.53
Mesenchymal stem cells. J Orthop Res (1991) 10.98
The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron (2008) 10.19
Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol (2013) 10.02
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol (2011) 9.68
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 9.42
Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science (2009) 8.80
Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain (1991) 8.16
Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun (1984) 8.14
Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci (2006) 8.09
The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement (2013) 7.69
The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet (1970) 7.16
TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol (2012) 7.01
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem (1986) 6.91
GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science (1993) 6.73
Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science (2002) 6.46
Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol (2000) 6.31
Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J (1992) 6.05
Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol (2004) 5.71
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol (1998) 5.47
2012 Alzheimer's disease facts and figures. Alzheimers Dement (2012) 5.43
Alzheimer's disease. Lancet (2011) 5.35
Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science (2001) 5.28
Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab (2003) 5.27
Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res (2005) 5.17
Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem (1987) 4.99
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med (2003) 4.51
A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med (2004) 4.37
Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells (2005) 4.26
Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature (1997) 4.01
The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry (1999) 3.98
Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev (2010) 3.69
The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells (2007) 3.68
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med (2005) 3.46
Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood (2007) 3.38
Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28
HEAT repeats in the Huntington's disease protein. Nat Genet (1995) 3.24
Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A (2007) 3.07
The spectrum of behavioral changes in Alzheimer's disease. Neurology (1996) 2.97
BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem (2007) 2.96
Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells (2004) 2.88
Criteria for diagnosing Parkinson's disease. Ann Neurol (1992) 2.78
Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A (1988) 2.78
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology (2003) 2.65
The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord (2012) 2.53
Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg (2005) 2.53
Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther (2009) 2.47
Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury. Bone Marrow Transplant (2007) 2.47
Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther (2012) 2.40
Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia (2003) 2.39
Ischemic rat brain extracts induce human marrow stromal cell growth factor production. Neuropathology (2002) 2.38
Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. Alzheimers Dement (2011) 2.26
Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther (2008) 2.25
Novel markers for the prospective isolation of human MSC. Ann N Y Acad Sci (2007) 2.24
Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol (2005) 2.24
GDNF signalling through the Ret receptor tyrosine kinase. Nature (1996) 2.21
Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke (2008) 2.18
Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol (2007) 2.17
Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. Transl Res (2009) 2.16
Good manufacturing practices production of mesenchymal stem/stromal cells. Hum Gene Ther (2010) 2.15
Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells (2012) 2.14
Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. Stem Cells (2004) 2.12
Functional interactions of neurotrophins and neurotrophin receptors. Annu Rev Neurosci (1995) 2.09
Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood (2013) 2.09
T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci (2005) 2.07
Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol (2009) 2.05
Stem cell paracrine actions and tissue regeneration. Regen Med (2010) 1.99
Gene delivery by lentivirus vectors. Mol Biotechnol (2007) 1.98
Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res (2008) 1.97
Genetic insights in Alzheimer's disease. Lancet Neurol (2013) 1.96
Genetics of Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.96
SDF-1 (CXCL12) is upregulated in the ischemic penumbra following stroke: association with bone marrow cell homing to injury. J Neuropathol Exp Neurol (2004) 1.94
Therapeutic potential of mesenchymal stem cell-derived microvesicles. Nephrol Dial Transplant (2012) 1.88
Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease. Am J Hum Genet (1995) 1.84
GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther (2013) 1.80
Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci U S A (1986) 1.77
Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J Neurosci (2004) 1.76
Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol (1999) 1.75
Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Res (2008) 1.72
Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol Ther (2011) 1.72
Adult bone marrow stromal cells administered intravenously to rats after traumatic brain injury migrate into brain and improve neurological outcome. Neuroreport (2001) 1.70
Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. Neurobiol Dis (2012) 1.70
Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med (2012) 1.69
Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J Neurochem (2006) 1.67
Cardiomyocyte microvesicles contain DNA/RNA and convey biological messages to target cells. PLoS One (2012) 1.67
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol (2012) 1.62
Isolation of human marrow-derived mesenchymal stem cells. Exp Hematol (2006) 1.60
Markers for characterization of bone marrow multipotential stromal cells. Stem Cells Int (2012) 1.59
Targeted gene addition to human mesenchymal stromal cells as a cell-based plasma-soluble protein delivery platform. Cytotherapy (2010) 1.58
Use of Genetically Altered Stem Cells for the Treatment of Huntington's Disease. Brain Sci (2014) 0.78